Sec Form 4 Filing - CR Group L.P. @ T2 Biosystems, Inc. - 2024-02-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person CR Group L.P. 2. Issuer Name and Ticker or Trading Symbol T2 Biosystems, Inc. [ TTOO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 1000 MAIN STREET, SUITE 2500 3. Date of Earliest Transaction (MM/DD/YY) 02/14/2024 (Street) HOUSTON, TX77002 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/14/2024 C 335,947 A 335,947 I By CRG Partners III (Cayman) Lev AIV I L.P. ( 2 ) Common Stock 02/14/2024 C 488,273 A 488,273 I By: CRG Partners III Parallel Fund B LP ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series B Preferred Stock ( 1 ) 02/14/2024 C 33,594.71 07/03/2023 ( 3 ) Common Stock 335,947 $ 0 0 I By: CRG Partners III (Cayman) Lev AIV I L.P. ( 2 ) Series B Preferred Stock ( 1 ) 02/14/2024 C 48,827.3 07/03/2023 ( 3 ) Common Stock 488,273 $ 0 10,875.25 I By: CRG Partners III Parallel Fund B LP ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other CR Group L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III (Cayman) Lev AIV I L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77022 X CRG Partners III - Parallel Fund B (Cayman) L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III - Parallel Fund (A) L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X CRG Partners III (Cayman) Unlev AIV I L.P. 1000 MAIN STREET, SUITE 2500 HOUSTON, TX77002 X Signatures /s/ Nathan D. Hukill, authorized signatory for CR Group LP, CRG Partners III LP, CRG Partners III Parallel Fund (A) LP, CRG Partners III Parallel Fund B LP, CRG Partners III (Cayman) Unlev AIV I LP, CRG Partners III (Cayman) Lev AIV I LP 02/16/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of Series B Preferred Stock converted into 10 shares of Common Stock for no additional consideration. ( 2 )CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities. ( 3 )The preferred stock has no expiration date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.